XML 43 R25.htm IDEA: XBRL DOCUMENT
v3.25.1

MesoScribe and Tantaline | 12 Months Ended
--- | ---
Dec. 31, 2024
Discontinued Operations and Disposal Groups [Abstract] |
MesoScribe and Tantaline | Note 14 – MesoScribe and Tantaline MesoScribe On August 8, 2023, the Company entered into a Purchase and License Agreement (the “Agreement”) with a third-party. Pursuant to the Agreement, the Company sold certain proprietary equipment relating to its plasma spray technology and material deposition system and granted a non-exclusive license to use certain of the Company’s related intellectual property as more fully described in the Agreement, for an aggregate adjusted purchase price of $0.8 million. The purchase price was payable in several installments and contingent upon certain performance metrics and other milestones. The Company received payments under the Agreement in the amount of $0.6 million which had been reflected as “deposits from purchaser” in the accompanying consolidated balance sheet as of December 31, 2023. The Company fulfilled remaining orders for MesoScribe products during 2024 at which time it ceased operations of MesoScribe and recorded a $0.7 million gain upon the completion of the sale of the equipment during the year ended December 31, 2024. During the year ended December 31, 2023, the Company recorded an impairment charge of $0.1 million for other equipment of MesoScribe. The revenues and net income of MesoScribe were $0.8 million and $1.1 million for the year ended December 31, 2024, including the gain on sale of equipment of $0.7 million. The revenues and net income of MesoScribe were $0.7 million and $33,000 for the year ended December 31, 2023, including the impairment charge of $0.1 million. CVD EQUIPMENT CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2024 and 2023 Note 14 – MesoScribe and Tantaline (continued) The total assets and total liabilities of the MesoScribe subsidiary were $0.6 million and $0, respectively, as of December 31, 2024 and $0.2 million and $0.7 million, respectively, as of December 31, 2023. Tantaline On May 26, 2023, the Company sold its Tantaline subsidiary located in Nordborg, Denmark in exchange for a nominal amount at closing and an earn-out provision based on any net income that Tantaline may earn during the five-year period ending December 31, 2027. The Company recorded a loss of $0.2 million upon the sale. Any earn-out amounts will be recognized when and if any such amounts become probable of receipt. The Company received a $6,000 earn-out payment in 2024 based on the results of Tantaline’s operations for the year ended December 31, 2023. Including the loss on disposition of $0.2 million, the revenues and net income of Tantaline were $0.5 million and $0.1 million, respectively, for the year ended December 31, 2023.

X
- References No definition available. + Details
Name: | us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-20/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContent + Details
Name: | us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration